



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Y. Nagai et al.
Title: Recombinant Sendai Virus
Appl. No.: 09/728,207
Filing Date: December 1, 2000
Examiner: M. Mosher
Art Unit: 1643
Atty Docket No: SPO-012C

#15
8/19/02
RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

Honorable Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This statement is being filed after a first Office action on the merits but before the mailing date of a final action or notice of allowance. Copies of the references listed in the Form PTO-1449 are enclosed herewith. Applicants' representative certifies that the enclosed documents were cited in a communication from the Japanese Office in a counterpart foreign application, Serial No. Hei-9-517214, mailed not more than three months prior to the filing date of this Information Disclosure Statement. A copy of this communication is also enclosed.

Thus, in accordance with 37 C.F.R. § 1.97(c)(2), Applicants submit that no fee is required.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: 08-12-02

Smith Patent Consulting, LLC
P.O. Box 2726
Alexandria, VA 22301
Telephone: (703) 549-7691
Facsimile: (703) 549-7692

By



Chalin A. Smith
Attorney for Applicant
Registration No. 41,569